What is the preferred concentration of ethanolamine oleate for sclerotherapy of oral vascular anomalies?

Camila O. Kato; Michel Campos Ribeiro; Mauro Henrique Nogueira Guimaraes Abreu; Soraya de Mattos Camargo Grossmann; Lucas G Abreu; Patrícia Carlos Caldeira; Ricardo Alves Mesquita

Ayuda

What is the preferred concentration of ethanolamine oleate for sclerotherapy of oral vascular anomalies?

Camila de Nazaré Alves de Oliveira Kato ^[1] ; Michel Campos Ribeiro ^[3] ; Mauro Henrique Nogueira Guimarães de Abreu ^[1] ; Soraya de Mattos Camargo Grossmann ^[2] ; Lucas Guimarães Abreu ^[1] ; Patrícia Carlos Caldeira ^[1] ; Ricardo Alves Mesquita ^[1]
1. [1] Universidade Federal de Minas Gerais
  
  Universidade Federal de Minas Gerais
  
  Brasil
2. [2] Pontifícia Universidade Católica de Minas Gerais
  
  Pontifícia Universidade Católica de Minas Gerais
  
  Brasil
3. [3] DDS, PhD, Oral and Maxillofacial Surgeon. Dept. of Oral and Maxillofacial Surgery, Hospital Márcio Cunha, Brazil
Mostrar afiliaciones +
Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 25, Nº. 4 (July), 2020
Idioma: inglés
Enlaces
- Texto completo
Resumen
- This study compared three different concentrations of EO (1.25%, 2.5% and 5%) for the treatment of oral vascular anomalies (OVAs).
  
  This was a retrospective comparative analysis of patients with OVAs treated with EO. Anomalies smaller than 20 mm were included. The patients were treated with 1.25% (G1), 2.5% (G2), and 5% (G3) and clinical data were obtained. The number of sessions, the final volume and dose of EO were statistically analyzed to verify effectiveness and safety of the treatment. The different concentrations of EO were compared considering the number of sessions, the final volume and total dose of EO. Analysis of covariance (ANCOVA) was used to evaluate the influence of covariates on the outcomes. A p-value < 0.05 was considered significant.
  
  Nineteen women and 11 men with a median age of 54 years were included. The OVAs were most frequent in the lip (n=14) and cheek (n=9). All lesions exhibited complete clinical healing within 28 days. Patients of G3 required fewer sessions than those of G2 (p=0.017), a lower final volume compared to the other groups (p<0.001), and a lower total dose than G1 (p<0.001). Patients of G1 used a lower total dose than G2 (p=0.003).
  
  The concentration of 5% EO performed better than 1.25% and 2.5% for sclerotherapy of OVAs measuring up to 20 mm. This preliminary result should be the preferred concentration of EO to provide an effective and safe treatment of OVAs.